Cargando…

Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons

BACKGROUND: This literature review assessed comparative efficacy and safety of long-acting muscarinic antagonist/long-acting β(2)-agonist (LAMA/LABA) fixed-dose combinations (FDCs) in patients with COPD and moderate-to-very severe airflow limitation, using evidence from direct (head-to-head) and ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurst, John R, Gruffydd-Jones, Kevin, Biswas, Mousumi, Guranlioglu, Deniz, Jenkins, Martin, Stjepanovic, Neda, Bamrara, Arushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336124/ https://www.ncbi.nlm.nih.gov/pubmed/32669839 http://dx.doi.org/10.2147/COPD.S230955

Ejemplares similares

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice
por: Ding, Bo, et al.
Publicado: (2020)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2018)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
por: Chen, Ching-Yi, et al.
Publicado: (2020)

Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
por: Gong, Yiwen, et al.
Publicado: (2022)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
por: Palli, Swetha R, et al.
Publicado: (2021)

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
por: Siddiqui, Mohd Kashif, et al.
Publicado: (2019)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
por: Rogliani, Paola, et al.
Publicado: (2022)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease
por: Yamada, Hideyasu, et al.
Publicado: (2017)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease
por: Azuma, Yoko, et al.
Publicado: (2021)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA
por: Vos, Wim, et al.
Publicado: (2016)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
por: Plate, Tanja, et al.
Publicado: (2020)

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework
por: Chen, Chun-Yu, et al.
Publicado: (2023)

And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?
por: Beeh, Kai M.
Publicado: (2018)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021)

Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
por: Plaza, Vicente, et al.
Publicado: (2023)

Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis
por: Lee, Hyun Woo, et al.
Publicado: (2020)

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
por: Han, MeiLan K., et al.
Publicado: (2018)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
por: Cheng, Wen-Chien, et al.
Publicado: (2020)

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5a75ok99luh2lrjko6feqv4620